Unum Therapeutics Inc (UMRX) Receives Average Rating of “Buy” from Brokerages

Unum Therapeutics Inc (NASDAQ:UMRX) has been assigned an average rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $17.25.

A number of research analysts have commented on the company. Zacks Investment Research downgraded Unum Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 21st. HC Wainwright started coverage on Unum Therapeutics in a report on Thursday, December 20th. They issued a “buy” rating and a $18.00 price target on the stock. Cowen started coverage on Unum Therapeutics in a report on Tuesday, February 26th. They issued a “market perform” rating on the stock. Finally, SunTrust Banks cut their price target on Unum Therapeutics to $10.00 and set a “buy” rating on the stock in a report on Friday. They noted that the move was a valuation call.

In related news, insider Seth Ettenberg sold 11,485 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $4.12, for a total value of $47,318.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Several hedge funds and other institutional investors have recently made changes to their positions in UMRX. Northern Trust Corp bought a new stake in shares of Unum Therapeutics in the 2nd quarter worth approximately $620,000. JPMorgan Chase & Co. increased its position in Unum Therapeutics by 2,782.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 20,753 shares of the company’s stock valued at $213,000 after acquiring an additional 20,033 shares during the period. Citadel Advisors LLC acquired a new stake in Unum Therapeutics in the 3rd quarter valued at approximately $235,000. Renaissance Technologies LLC acquired a new stake in Unum Therapeutics in the 3rd quarter valued at approximately $723,000. Finally, Jane Street Group LLC acquired a new stake in Unum Therapeutics in the 3rd quarter valued at approximately $150,000. 47.63% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:UMRX opened at $4.39 on Friday. Unum Therapeutics has a 52 week low of $3.60 and a 52 week high of $17.66.

Unum Therapeutics (NASDAQ:UMRX) last released its earnings results on Thursday, March 28th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Unum Therapeutics had a negative return on equity of 382.71% and a negative net margin of 404.34%. The company had revenue of $3.80 million for the quarter, compared to the consensus estimate of $2.58 million. On average, sell-side analysts anticipate that Unum Therapeutics will post -1.44 earnings per share for the current year.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

See Also: Bid-Ask Spread

Analyst Recommendations for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.